Robust localization of poorly visible tumor in fiducial free stereotactic body radiation therapy.

Background And Purpose: Effective respiratory motion management reduces healthy tissue toxicity and ensures sufficient dose delivery to lung cancer cells in pulmonary stereotactic body radiation therapy (SBRT) with high fractional doses. An articulated robotic arm paired with an X-ray imaging system is designed for real-time motion-tracking (RTMT) dose delivery. However, small tumors (<15 mm) or tumors at challenging locations may not be visible in the X-ray images, disqualifying patients with such tumors from RTMT dose delivery unless fiducials are implanted via an invasive procedure. To track these practically invisible lung tumors in SBRT, we hereby develop a deep learning-enabled template-free tracking framework, SAFE Track.

Methods: SAFE Track is a fully supervised framework that trains a generalizable prior for template-free target localization. Two sub-stages are incorporated in SAFE Track, including the initial pretraining on two large-scale medical image datasets (DeepLesion and Node21) followed by fine-tuning on our in-house dataset. A two-stage detector, Faster R-CNN, with a backbone of ResNet50, was selected as our detection network. 94 patients (415 fractions; 40,348 total frames) with low tumor visibility who thus had implanted fiducials were included. The cohort is categorized by the longest dimension of the tumor (<10 mm, 10-15 mm and > 15 mm). The patients were split into training (n = 66) and testing (n = 28) sets. We simulated fiducial-free tumors by removing the fiducials from the X-ray images. We classified the patients into two groups - fiducial implanted inside tumors and implanted outside tumors. To ensure the rigor of our experiment design, we only conducted fiducial removal simulation in training patients and utilized patients with fiducial implanted outside of the tumors for testing. Commercial Xsight Lung Tracking (XLT) and a Deep Match were included for comparison.

Results: SAFE Track achieves promising outcomes to as accurate as 1.23±1.32 mm 3D distance in testing patients with tumor size > 15 mm where Deep Match is at 4.75±1.67 mm and XLT is at 12.23±4.58 mm 3D distance. Even for the most challenging tumor size (<10 mm), SAFE Track maintains its robustness at 1.82 plus or minus 1.67 mm 3D distance, where Deep Match is at 5.32 plus or minus 2.32 mm, and XLT is at 24.83±12.95 mm 3D distance. Moreover, SAFE Track can detect some considerably challenging cases where the tumor is almost invisible or overlapped with dense anatomies.

Conclusion: SAFE Track is a robust, clinically compatible, fiducial-free, and template-free tracking framework that is applicable to patients with small tumors or tumors obscured by overlapped anatomies in SBRT.